[
  {
    "ts": null,
    "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
    "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
    "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756285140,
      "headline": "Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic",
      "id": 136536358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Dyslipidemia, linked to elevated cardiovascular disease risk, is benefiting from advancements in lipid profiling and genetic testing, catalyzing demand for personalized treatments. Statins dominate therapy, supported by PCSK9 inhibitors and RNA-based medicines. However, challenges like medication non-compliance, side effects, and high drug costs, especially in lower-income regions, impede market expansion. Yet, proactive government initiatives and heightened research funding are improving treatm",
      "url": "https://finnhub.io/api/news?id=459030ebf78534849e2c06f68d0a59a57cd09453cecbb0b13f1d5e1fe019216b"
    }
  }
]